Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

68.66 +0.95 (+1.41%)
Streaming Delayed Price Updated: 1:20 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
84 85 Next >
Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs
MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations. 
Via Benzinga
Elon Musk Backs Satya Nadella's View That AI Must Produce 'Socially Useful' Results: 'The Real Question In The Next Five Years Is...'
Tesla (NASDAQ: TSLA) CEO Elon Musk endorsed Microsoft (NASDAQ: MSFT) Satya Nadella's perspective on the practical impact of AI, emphasizing its benefits to sectors like healthcare, education, and... 
Via Benzinga
Topics Artificial Intelligence
Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover?
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies. 
Via The Motley Fool
Topics Intellectual Property
Massive News for Hims & Hers Stock Investors!
Via The Motley Fool
GLP-1 Showdown In India: Eli Lilly’s Mounjaro Pen Approved Just Days After Novo’s Wegovy Launch
Local drugmakers, including Sun Pharma, Biocon, Zydus, Cipla, and Dr. Reddy’s are racing to develop cheaper versions of semaglutide as its Indian patent nears expiry. 
Via Stocktwits
Topics Intellectual Property
This Weight Loss Partnership Was a Short One
Via The Motley Fool
Topics Economy
Why Hims & Hers Stock Is Crashing, and Is It a Buying Opportunity?
Via The Motley Fool
Why Shares in Novo Nordisk Lost Weight Today
Via The Motley Fool
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years. 
Via Benzinga
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Abbott, Dexcom Draw Retail Buzz As RFK Jr. Urges Americans To Embrace Health Wearables
Retail sentiment surged on Stocktwits, with message volume jumping 1,600% for Abbott and 750% for Dexcom. 
Via Stocktwits
Hims & Hers CEO Says 'No Way In Hell We're Gonna Cave On' Selling Compounded Obesity Drugs After Novo Nordisk Breakup
Truist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the stock. 
Via Stocktwits
Topics Law Enforcement Lawsuit
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?
Telehealth company Hims & Hers (HIMS) saw a 34% stock drop after Novo Nordisk (NVO) ended their relationship. Investors must decide if it's a buying opportunity or a warning sign for the industry. 
Via Benzinga
Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly
Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio. 
Via Benzinga
Why Did Hims and Hers Stock Crash on Monday?
Via The Motley Fool
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Via The Motley Fool
Hims & Hers Stock Rebounds After-Hours After Novo Nordisk Split Triggers Record Plunge — Retail Traders Stay Loyal
On Stocktwits, 24-hour message volume around HIMS soared 6,717% — the fifth highest among healthcare stocks. It was the top trending ticker on the platform late Monday. 
Via Stocktwits
Hims & Hers CEO Hits Back At Novo Nordisk After Abrupt End Of Collaboration, Alleges Wegovy-Maker Is ‘Misleading The Public’
HIMS CEO said that the pharma company’s commercial team has been increasingly pressuring the company to control clinical standards and steer patients to Wegovy regardless of whether it is clinically... 
Via Stocktwits
Why Novo Nordisk Stock Is Sinking Today
Via The Motley Fool
Topics Stocks Supply Chain
Stocks Rise, Oil Tumbles Despite Iran's Strikes On US Bases: What's Driving Markets Monday?
Wall Street resilient as Iran fires missiles at U.S. bases in Qatar and Iraq, defying expectations in energy market. U.S. equities and gold up, bonds down. 
Via Benzinga
Topics Bonds
Hims & Hers Stock Plunges As Novo Nordisk Ends Partnership Over Allegations Of Selling Knockoff Versions Of Wegovy
Novo said that Hims & Hers failed to adhere to the law, which prohibits mass sales of compounded drugs. It alleged that the telehealth operator is promoting and selling illegitimate, knockoff versions... 
Via Stocktwits
Topics Law Enforcement
Hims & Hers Health Stock Is Tumbling Monday: What's Happening?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company. 
Via Benzinga
Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern
Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals. 
Via Benzinga
IBD 50's Hims Plummets After Novo Yanks Deal Over 'Deceptive' And 'Illegitimate' Wegovy Knockoffs
Hims stock plummeted Monday after Novo Nordisk ended their collaboration over concerns about Hims' compounded semaglutide. 
Via Investor's Business Daily
Dow Futures Edge Lower As Iran Moves To Block Strait Of Hormuz: Exxon, Chevron, Occidental, Tesla Among Stocks In Focus
Via Stocktwits
Topics Stocks
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Reasonable Valuation
NOVO-NORDISK (NYSE:NVO) offers strong growth, high profitability, and reasonable valuation, making it an attractive candidate for investors seeking affordable growth stocks. 
Via Chartmill
Watch Out, Novo Nordisk & Eli Lilly: Chinese Biotech Steps Into the Ring To Take On Global Weight-Loss Leaders
Sciwind Biosciences is expanding its global footprint with licensing deals and early talks for overseas development, as it eyes a double-digit market share in China's fast-growing obesity drug sector. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
84 85 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.